Welcome to our dedicated page for Connect Biopharma Holdings news (Ticker: CNTB), a resource for investors and traders seeking the latest updates and insights on Connect Biopharma Holdings stock.
Connect Biopharma Holdings Limited reports clinical and corporate developments for a clinical-stage biopharmaceutical company focused on inflammatory diseases. Its principal program is rademikibart, an antibody designed to target interleukin-4-receptor alpha, with company updates centered on asthma, chronic obstructive pulmonary disease and moderate-to-severe atopic dermatitis.
Recurring news includes rademikibart clinical data, Seabreeze STAT asthma and COPD study updates, Data Monitoring Committee and regulatory-related disclosures, partner activity involving Simcere in China, financial results, financing activity, investor conference participation and governance matters.
Connect Biopharma (Nasdaq: CNTB) has appointed Jiang Bian as General Counsel & Chief Compliance Officer, effective August 20, 2021. Bian brings extensive experience from Guardant Health and Pieris Pharmaceuticals, focusing on legal issues in healthcare and biopharma. Additionally, Jean Liu has joined the Board of Directors as an Independent Director, contributing over 20 years of biotech experience. These appointments aim to strengthen executive leadership and support Connect Biopharma's growth strategy, particularly in developing therapies for chronic inflammatory diseases.
Connect Biopharma (Nasdaq: CNTB) announced that Dr. Zheng Wei, Co-Founder & CEO, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 10:00 am ET. The event aims to discuss the company's advancements in therapies for chronic inflammatory diseases, including their lead products CBP-201 and CBP-307. A live webcast can be accessed on Connect Biopharma's Investor Relations page, with a replay available post-event. The company is dedicated to innovative T cell-driven research.
Connect Biopharma (Nasdaq: CNTB) has announced the first dosing of a subject in a Phase I clinical trial for CBP-174, a novel oral treatment for chronic inflammatory pruritus. This double-blind, placebo-controlled trial aims to assess safety, tolerability, and pharmacokinetics of CBP-174, targeting patients suffering from chronic itch, particularly those with atopic dermatitis. The trial follows promising preclinical results showing rapid relief from itching. CEO Zheng Wei emphasized the importance of addressing unmet needs in pruritus management, highlighting CBP-174's potential to complement existing therapies.
Connect Biopharma (Nasdaq: CNTB) announced the initiation of a Phase 2 trial for CBP-201, targeting adults with moderate-to-severe persistent asthma. The trial aims to enroll about 300 patients across 80 sites globally, assessing the efficacy and safety of two SC doses of CBP-201. This treatment blocks IL-4 receptor alpha to mitigate allergic inflammation. CEO Zheng Wei emphasized the potential of CBP-201 to address significant unmet medical needs in asthma patients.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) has completed full enrollment for its phase 2 clinical trial of CBP-201, targeting adult patients with moderate-to-severe Atopic Dermatitis (AD). The trial aims to assess CBP-201's safety, efficacy, and pharmacokinetics over 16 weeks, involving 220 participants across 60 sites globally. CEO Zheng Wei expressed optimism for the trial results, expected later this year, highlighting the unmet needs in treating AD. CBP-201 has shown favorable outcomes in earlier trials, indicating potential for a differentiated profile compared to existing therapies.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) has successfully closed its initial public offering of 12,937,500 American Depositary Shares (ADSs) at a price of $17.00 per ADS, raising approximately $219.9 million in gross proceeds. This offering included the full exercise of an underwriters’ option for an additional 1,687,500 ADSs. The ADSs commenced trading on March 19, 2021, on the Nasdaq Global Market. The company is focused on developing therapies for chronic inflammatory diseases, with lead candidates including CBP-201 and CBP-307.
Connect Biopharma Holdings Limited announced the pricing of its initial public offering (IPO) of 11,250,000 American Depositary Shares (ADSs) at $17.00 per ADS, aiming for gross proceeds of approximately $191.3 million, or $219.9 million if underwriters fully exercise their option to purchase additional shares. The ADSs will trade on the Nasdaq under the symbol 'CNTB' starting March 19, 2021, and the offering is set to close by March 23, 2021. This capital will advance its T-cell-driven therapies for chronic inflammatory diseases, including lead candidates CBP-201 and CBP-307.